Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis –
Are there any partnership or licensing opportunities tied to the RESET‑Myositis trial that could impact the stock?
How does the sentiment score of 35 influence market perception, and have analysts adjusted their ratings or price targets?
What are the potential dilution effects from any planned equity raises or option exercises?
21 days ago